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keeping with current enthusiasm around
proteomics technologies. But perhaps this
new spin will reawaken flow cytometry’s
proven record as a robust means of quan-
titatively assessing protein expression at
the individual cell level. Third, the authors
demonstrate that this approach can be
taken not only with established cell lines,
but also with primary leukemic blasts.
Indeed, a significant amount of hetero-
geneity in cellular response was observed
within individual patient samples.Whether
this heterogeneity will prove to be clinical-
ly important remains to be determined.
To be sure, the study is limited by the
small numbers of analytes (e.g., Stat
proteins) and small number of perturba-
tions (cytokine stimulations). But, the
proof of principle is established that clas-
sification based on dynamic response to
perturbation is feasible and informative.
As higher complexity proteomic profiling
methods are established, they should be
able to be utilized within this same con-
ceptual framework. Less clear is whether
or not specific new insights into signal
transduction in leukemia were garnered
by this study. Similarly, the sparseness of
the data makes it difficult to form a true
network understanding of signaling in
these cells.
Nevertheless, the study does raise
the provocative notion that a functional
taxonomy of cancer—that is, a taxonomy
built on functional response (however
measured) to a diverse set of cellular per-
turbations—could be highly informative.
Of course there are at present numerous
technical limitations to the widespread
application of this approach to solid
tumors, but the principle is indeed estab-
lished, and the study will hopefully prompt
others to use the tools of genomics and
high dimensionality data analysis and
bring them to bear on studying the func-
tional consequences of perturbation of
cancer cells. Such efforts will at last put
the functional in functional genomics.
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Imatinib, a selective inhibitor of the ABL
tyrosine kinase, is a highly effective
treatment for chronic myeloid leukemia
(CML), a disease driven by the activated
BCR-ABL tyrosine kinase. Relapses
after an initial response have occurred in
a small percentage of chronic phase
patients, but are quite common in
patients with advanced disease. In the
majority of cases, resistance is caused
by reactivation of BCR-ABL kinase activ-
ity, indicating that resistance could be
overcome if inhibition of BCR-ABL was
restored. After the original report of a
threonine to isoleucine substitution at
amino acid 315 (T315I) (Gorre et al.,
2001), it has become clear that muta-
tions in the kinase domain of BCR-ABL
are the predominant mechanism under-
lying acquired drug resistance, although
some patients have amplification of
BCR-ABL (Hochhaus et al., 2002; Shah
et al., 2002). Mutations have now been
observed in at least 17 different amino
acids scattered throughout the ABL
kinase domain and render the kinase
variably less sensitive to imatinib (Shah
et al., 2002; Corbin et al., 2003).
Once it became clear that resistance
to imatinib was frequently due to muta-
tions of BCR-ABL, alternative inhibitors
that could inhibit these ABL mutants
were sought. The first compound identi-
fied with this capability, PD180970, a
pyridopyrimidine derivative, had original-
ly been developed as a SRC kinase
inhibitor, but was subsequently shown to
inhibit wild-type ABL at nanomolar con-
centrations (Dorsey et al., 2000). Based
on structural data discussed later, we
reasoned that SRC/ABL inhibitors would
likely inhibit the kinase domain mutants
detected in patients and showed, with
the notable exception of T315I, that
PD180970 inhibited all imatinib-resistant
BCR-ABL kinase domain mutants tested
in vitro (La Rosee et al., 2002). Although
the unfavorable pharmacokinetic profile
of the pyridopyrimidine derivatives pre-
cluded their clinical development, these
studies provided proof of principle for the
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The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial
response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism dri-
ving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations,
and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mecha-
nism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These
studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.
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concept that imatinib resis-
tance due to kinase domain
mutations could be over-
come with alternative ABL
inhibitors. A number of other
SRC/ABL inhibitors, includ-
ing other pyridopyrimidines
and AP23464, a trisubstitut-
ed purine, have been tested
in vitro and consistently
demonstrate that imatinib-
resistant BCR-ABL kinase
domain mutations, with the
exception of T315I, are inhib-
ited by these compounds
(Huron et al., 2003; O’Hare et
al., 2004).
A recent report in
Science extends these
observations on a similar
SRC/ABL inhibitor to in vivo
studies. In the study by Shah
et al., orally administered
BMS-354825 was shown to
block BCR-ABL kinase activi-
ty in a murine leukemia
model (Shah et al., 2004).
Survival of mice injected with
cells expressing wild-type or
M351T mutant BCR-ABL was prolonged,
while the drug was ineffective against
tumors expressing the T315I mutant of
BCR-ABL. These results raise hopes
that BMS-354825 may be effective 
in patients with sensitive BCR-ABL
mutants and provide an effective treat-
ment option for many patients with ima-
tinib resistance. In addition, the greater
potency of the compound may induce
responses in patients with overexpres-
sion of BCR-ABL. As BMS-354825 is
currently in Phase I clinical trials, results
from these studies should be available
soon.
The crystal structure of ABL with
imatinib and a pyridopyrimidine has pro-
vided crucial insights into the mecha-
nism of action of imatinib and alternative
ABL kinase inhibitors. Kinase domains
exhibit a canonical bi-lobar structure,
with the catalytic site lining the groove
between the N- and C-terminal lobes
(Figure 1). Kinase activity is regulated by
the position of the activation loop, a flexi-
ble structure that assumes distinct con-
formations in the inactive and active
states. Unexpectedly, imatinib binds to
the ABL kinase domain in its unique
inactive conformation, with the activation
loop in the closed position (Schindler et
al., 2000). Given that the activation loops
of active kinases assume
very similar conformations,
while their inactive con-
formations are distinct, this
explained the ability of ima-
tinib to inhibit ABL, but not
SRC. These two kinases
have a high degree of amino
acid homology in their kinase
domains, but adopt unique
conformations in their inac-
tive states. In contrast to
imatinib, the pyridopyrimidine
derivative PD173955 was
found to bind to ABL indepen-
dently of the conformation of
the activation loop, indicating
that binding was not influ-
enced by the activation state
of the kinase (Nagar et al.,
2002). Another significant dif-
ference between the two
inhibitors was their mode of
binding to the P loop, the site
that normally accommodates
the phosphate groups of ATP.
Whereas the P loop under-
goes extensive conformational
changes on imatinib binding,
there are only minimal rearrangements
in the complex with PD173955 (Figures
1 and 2). Since the active conformations
of kinases are much more similar than
their inactive conformations and the
structural requirements for binding
compounds such as PD173955 are
much less stringent than imatinib, it is
likely that PD173955 and related com-
pounds such as BMS-354825 will be
less specific than imatinib. This raises
the possibility that these compounds
could have more long-term side effects,
including immunosuppression due to
SRC inhibition.
These crystal structures have also
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Figure 1. Imatinib (IM) and PD173955 (PD) in complex with the ABL
kinase domain
A: Imatinib occupies most of the interlobar groove of the kinase
domain, capturing the kinase in a unique inactive conformation. The
activation loop (blue) is in the closed position, preventing substrate
binding. 
B: PD173955 occupies much less surface area. Most importantly, the
kinase is in an active state with the activation loop (red) in an open
conformation. Note that imatinib would encounter a significant steric
clash with the activation loop in the active conformation. Modified
from Nagar et al. (2002) with permission.
Figure 2. Structural changes in the P loop
induced by imatinib binding
The P loop of the active insulin receptor
kinase (right) bound to a nucleotide is
shown. Note the nearly vertical position of
the P loop in this structure. On the left, the
massive distortions induced in the P loop
(green) to accommodate imatinib binding
are shown. Modified from Shah et al. (2002)
with permission.
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provided significant insights into the
mechanism of resistance of the various
ABL mutants to imatinib and why they
are sensitive to the SRC/ABL inhibitors.
Imatinib contacts more than 20 amino
acids in the ABL kinase domain, most 
of which are not contact sites for
PD173955. Substitutions of any of these
residues can lead to a steric clash 
with imatinib, but not with PD173955.
Mutations within the P loop may impair
the ability of the P loop to undergo the
extensive conformation changes that are
required for imatinib binding. These
mutations would be much less likely to
block the minor conformational adjust-
ment necessary for binding of pyridopy-
rimidines. Other mutations probably
result in a kinase in which the open or
active conformation of the activation loop
is favored. As shown in Figure 1B,
PD173955 can bind to this conformation
of the kinase, but imatinib encounters a
significant steric clash with the activation
loop in this open conformation. This
mechanism is likely responsible for the
resistance of activation loop mutants and
of mutations that affect sites with a role
for the auto-inhibition of ABL.This leaves
the T315I mutant, which is resistant to all
inhibitors reported thus far. T315 makes
a hydrogen bond with imatinib, and there
is a van der Waals interaction of this
residue with PD173955. Thus, resis-
tance could be due to loss of this interac-
tion. It is also possible that any bulky
substitution at position 315 prevents
drug binding due to steric hindrance. It
should be emphasized that the crystal
structure of the ABL kinase domain in
complex with alternative ABL inhibitors
other than PD173955 has not yet been
reported. However, the fact that their
activity profiles against the various
mutants are comparable argues that
they have a similar mode of binding.
An interesting prospect is that com-
binations of imatinib with BMS-354825
may delay or prevent the emergence of
resistant clones, analogous to targeted
therapy of HIV infection. Most CML
patients on imatinib, including those
treated in early chronic phase, harbor
residual leukemia. The precise mecha-
nism underlying the persistence of resid-
ual disease has not been defined, but it
is conceivable that a more potent ABL
kinase inhibitor may be capable of eradi-
cating these residual leukemic cells.
Alternatively, low levels of mutant clones
could contribute to the disease persis-
tence, and alternative ABL inhibitors
could also allow the eradication of these
leukemic cells. The success of this
approach will ultimately depend on the
prevalence of T315I mutant clones and
their contribution to disease persistence.
Many patients with imatinib resistance
harbor multiple different mutations (Shah
et al., 2002), and the frequency of
“occult” T315I mutant clones could be
higher than expected. Thus, even under
the selective pressure of an inhibitor
combination, the resistant T315I mutant
may emerge as the default mutant. It is
also possible that hitherto unknown
resistant mutants will be selected.
Regardless, all of this is good news
for patients with CML. First there was the
identification and characterization of
imatinib. Then, there was the identifica-
tion of the mechanism of resistance and
the discovery of compounds capable of
circumventing resistance. Now there is a
clinically viable compound that has
entered clinical trials for patients with
imatinib resistance, and we eagerly
await the results of these trials.
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